VentriPoint Diagnostics Ltd. (VPT.V) said that Mayo Clinic has joined its multi-centre clinical trial to evaluate the use of an ultrasound diagnostic tool for patients with pulmonary arterial hypertension. Robert Frantz, M.D., a consultant in the Cardiovascular Division and Associate Professor of Medicine, College of Medicine, Mayo Clinic is the lead investigator for the clinical trial site in Rochester, MN.
The VMS is for investigational use only in the United States and is approved for sale and clinical use in Canada and Europe. VentriPoint is pursuing US-FDA approval through the 510(k) process.
For comments and feedback: editorial@rttnews.com